ArticleRevista da Associacao Medica Brasileira (1992)2025
Metabolic parameters in F-fluorodeoxyglucose positron emission tomography/computed tomography for treatment response in colorectal carcinoma.
Article in Revista da Associacao Medica Brasileira (1992), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn daily practice, 18F-fluorodeoxyglucose positron emission tomography/computed tomography plays a crucial role in the clinical follow-up to evaluate treatment response and detect recurrence in patients with elevated serum tumor markers. In this research, we aimed to elucidate whether there was a correlation between markers and semiquantitative-metabolic parameters.
methodsIn this study, 66 patients who applied to our institution with a histopathological diagnosis of colorectal carcinoma and had two consecutive 18F-fluorodeoxyglucose positron emission tomography/computed tomography scans for diagnosis or response to treatment were enrolled. The obtained images were evaluated based on response evaluation criteria in solid tumors and positron emission tomography response criteria in solid tumors criteria. The patients were divided into two groups: regression patient group (n=45) and progression patient group (n=21).
resultsThere was a high positive correlation between whole body-total lesion glycolysis and serum tumor marker (r=0.618, p=0.000), a moderate positive correlation between SUVmax (standardized uptake value) and primary tumor-total lesion glycolysis and serum tumor marker (r=0.497, p=0.001; r=0.511, p=0.000), and a weak positive correlation between SUVmean and whole body-metabolic tumor volume and serum tumor marker (r=0.435, p=0.003) in patients achieving regression. There was a moderate positive correlation between whole body-total lesion glycolysis and tumor marker in the progression group (r=0.596, p=0.004) and a weak positive correlation between SUVmax, SUVmean, total lesion glycolysis, whole body-metabolic tumor volume, and tumor marker in the progression group (r=0.343, p=0.128; r=0.299, p=0.188; r=0.279, p=0.220; r=0.374, p=0.095).
conclusionWe concluded that 18F-fluorodeoxyglucose positron emission tomography/computed tomography will provide beneficial outcomes in evaluating treatment response and detecting recurrent disease in patients with colorectal carcinoma. In this context, the whole body-total lesion glycolysis value is the most sensitive parameter that can be an alternative to SUVmax in predicting treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.